Ian C Harding1, Ronodeep Mitra2, Solomon A Mensah1, Alina Nersesyan1, Nandita N Bal2, Eno E Ebong1,2,3. 1. Department of Bioengineering, Northeastern University, Boston, MA, USA. 2. Department of Chemical Engineering, Northeastern University, Boston, MA, USA. 3. Department of Neuroscience, Albert Einstein College of Medicine, New York, NY, USA.
Abstract
BACKGROUND: The onset of many disease processes depends on the function of the endothelial cell (EC) glycocalyx (GCX) which acts as a flow-dependent barrier to cellular infiltration and molecular transport across the blood vessel wall. OBJECTIVE: This review aims to examine these processes with the potential end goal of implementing GCX repair to restore EC barrier function and slow the progression of disease. METHODS: Cell and mouse studies were employed to examine the state of EC GCX in healthy versus disruptive flow conditions. Correlations of observations of the GCX with a number of EC functions were sought with an emphasis on studies of trans-endothelial barrier integrity against vessel wall infiltration of cells and molecules from the circulation. To demonstrate the importance of GCX as a regulator of trans-endothelial infiltration, assays were performed using ECs with an intact GCX and compared to assays of ECs with an experimentally degraded GCX. Studies were also conducted of ECs in which a degraded GCX was repaired. RESULTS: In healthy flow conditions, the EC GCX was found to be thick and substantially covered the endothelial surface. GCX expression dropped significantly in complex flow conditions and coincided with a disease-like cellular and molecular accumulation in the endothelium or within the blood vessel wall. Therapeutic repair of the GCX abolished this accumulation. CONCLUSIONS: Regenerating the degraded GCX reverses EC barrier dysfunction and may attenuate the progression of vascular disease.
BACKGROUND: The onset of many disease processes depends on the function of the endothelial cell (EC) glycocalyx (GCX) which acts as a flow-dependent barrier to cellular infiltration and molecular transport across the blood vessel wall. OBJECTIVE: This review aims to examine these processes with the potential end goal of implementing GCX repair to restore EC barrier function and slow the progression of disease. METHODS: Cell and mouse studies were employed to examine the state of EC GCX in healthy versus disruptive flow conditions. Correlations of observations of the GCX with a number of EC functions were sought with an emphasis on studies of trans-endothelial barrier integrity against vessel wall infiltration of cells and molecules from the circulation. To demonstrate the importance of GCX as a regulator of trans-endothelial infiltration, assays were performed using ECs with an intact GCX and compared to assays of ECs with an experimentally degraded GCX. Studies were also conducted of ECs in which a degraded GCX was repaired. RESULTS: In healthy flow conditions, the EC GCX was found to be thick and substantially covered the endothelial surface. GCX expression dropped significantly in complex flow conditions and coincided with a disease-like cellular and molecular accumulation in the endothelium or within the blood vessel wall. Therapeutic repair of the GCX abolished this accumulation. CONCLUSIONS: Regenerating the degraded GCX reverses EC barrier dysfunction and may attenuate the progression of vascular disease.
Authors: Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink Journal: Pflugers Arch Date: 2007-01-26 Impact factor: 3.657
Authors: Thomas D Nightingale; Matthew E F Frayne; Steven Clasper; Suneale Banerji; David G Jackson Journal: J Biol Chem Date: 2008-11-25 Impact factor: 5.157
Authors: Daniel Chappell; Bernhard Heindl; Matthias Jacob; Thorsten Annecke; Congcong Chen; Markus Rehm; Peter Conzen; Bernhard F Becker Journal: Anesthesiology Date: 2011-09 Impact factor: 7.892
Authors: Anurag Singh; Raina D Ramnath; Rebecca R Foster; Emma C Wylie; Vincent Fridén; Ishita Dasgupta; Borje Haraldsson; Gavin I Welsh; Peter W Mathieson; Simon C Satchell Journal: PLoS One Date: 2013-02-14 Impact factor: 3.240
Authors: Sebastian Grundmann; Stephan H Schirmer; Liesbeth H P Hekking; Jan Andries Post; Mihaela G Ionita; Daphne de Groot; Niels van Royen; Bernard van den Berg; Hans Vink; Martin Moser; Christoph Bode; Dominique de Kleijn; Gerard Pasterkamp; Jan J Piek; Imo E Hoefer Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310
Authors: Solomon A Mensah; Alina A Nersesyan; Ian C Harding; Claire I Lee; Xuefei Tan; Selina Banerjee; Mark Niedre; Vladimir P Torchilin; Eno E Ebong Journal: FASEB J Date: 2020-03-13 Impact factor: 5.191
Authors: Ming J Cheng; Ronodeep Mitra; Chinedu C Okorafor; Alina A Nersesyan; Ian C Harding; Nandita N Bal; Rajiv Kumar; Hanjoong Jo; Srinivas Sridhar; Eno E Ebong Journal: Ann Biomed Eng Date: 2020-02-18 Impact factor: 3.934
Authors: Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes Journal: BMC Med Date: 2020-10-19 Impact factor: 8.775
Authors: Hans Vink; Philipp Kümpers; Alexandros Rovas; Jan Sackarnd; Jan Rossaint; Stefanie Kampmeier; Hermann Pavenstädt Journal: Crit Care Date: 2021-03-19 Impact factor: 9.097